据独家消息披露，包括辉瑞(Pfizer)、赛诺菲(Sanofi)、葛兰素史克(GSK)、诺华(Novartis)及勃林格殷格翰(Boehringer Ingelheim)在内的多家跨国制药巨头近期上调了药品价格。值得注意的是，这些企业此前均与美国特朗普政府达成了药品定价相关协议。
此次调价涉及多款处方药与疫苗产品，引发市场对医疗成本上升的担忧。尽管制药企业声称提价主要源于研发投入增加与通胀压力，但消费者权益组织批评此举将加剧患者用药负担。
行业分析师指出，在政府定价协议框架下仍执行涨价策略，反映出药企在政策约束与利润追求间的复杂博弈。未来药品定价监管趋势与药企战略调整将成为行业关注焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.